Prosensa Shares Up on FDA Path Forward for Drisapersen

June 3, 2014 12:30 PM

6 0

Prosensa Holding NV (RNA) said the U.S. Food and Drug Administration outlined a path forward for potential accelerated approval of its drisapersen treatment for Duchenne Muscular Dystrophy, a rare muscular disorder.

The Dutch biotechnology company's shares rose 13% to $11.98 in premarket trading, as it confirmed that it will pursue a new drug application later this year in the U.S.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page